GeneMatrix Inc. (KOSDAQ:109820)

Market Cap	52.31B
Revenue (ttm)	4.72B
Net Income (ttm)	-2.09B
Shares Out	20.39M
EPS (ttm)	-123.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,781
Average Volume	106,096
Open	2,705.00
Previous Close	2,690.00
Day's Range	2,600.00 - 2,705.00
52-Week Range	2,270.00 - 7,180.00
Beta	-1.34
RSI	38.95
Earnings Date	n/a

About GeneMatrix

GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and contro...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 109820

Financial Performance

In 2018, GeneMatrix's revenue was 4.73 billion, a decrease of -8.75% compared to the previous year's 5.19 billion. Losses were -3.11 billion, 111.4% more than in 2017.